Serum decoy receptor 3 is a biomarker for disease severity in nonatopic asthma patients

Abstract

Decoy receptor 3 (DcR3), a soluble receptor of the tumor necrosis factor receptor superfamily, is a pleiotropic immunomodulator. The aim of this study was to investigate serum DcR3 levels in atopic and nonatopic asthma patients. The serum DcR3 levels of 70 adults with asthma and 20 healthy controls were determined by enzyme-linked immunosorbent assay (ELISA). The asthma patients were divided into atopic and nonatopic subgroups, based on the presence or absence of immunoglobulin E (IgE) specific to allergen. Correlations between serum DcR3 levels and blood total-eosinophil counts, forced expiratory volume in 1second (FEV1), FEV1/forced vital capacity (FVC), and Asthma Control Test (ACT) scores were analyzed. The mean serum DcR3 level was significantly higher in asthma patients than in healthy controls (266.1±60.6pg/mL vs. 63.7±21.9pg/mL, p=0.003), but there was no significant difference between the mean serum DcR3 level of asthma patients with atopy (37 patients) and patients without atopy (33 patients; 298.7±111.2pg/mL vs. 230.6±38.5pg/mL, p=0.064). However, the serum DcR3 level was positively correlated with the total eosinophil count (r=0.448, p=0.012) and inversely correlated with the percentages of predicted FEV1, FEV1/FVC, and ACT score (r=0.409, p=0.018; r=-0.399, p=0.021; and r=-0.505, p=0.003, respectively) in nonatopic asthma patients, but not in atopic patients. High serum DcR3 levels are associated with disease severity in nonatopic asthma patients, which suggests that DcR3 is a potential biomarker that can be used to predict the severity of nonatopic asthma.